立体定向体部放疗联合化疗对大体积(≥5厘米)非小细胞肺癌总生存的影响
该分析基于美国国家癌症数据库2004至2012年数据,纳入201例接受SBRT(≤10次)的原发性≥5cm非小细胞肺癌患者。中位总生存期为25.1个月,15%患者接受化疗;化疗与更长总生存相关(中位30.6 vs 23.4个月,P=.027),多变量分析中化疗仍独立关联改善总生存(HR 0.57,P=.039)。
要点
- ≥5cm非小细胞肺癌接受SBRT(≤10次)的中位总生存期为25.1个月。
- 15%患者接受化疗,化疗组中位总生存期30.6个月优于未化疗组23.4个月(P=.027)。
- 多变量分析显示化疗独立关联改善总生存(HR 0.57,P=.039)。
核心结论
- SBRT对≥5cm的非小细胞肺癌有治疗价值,化疗与改善总生存相关。
研究设计与样本
- 查询美国国家癌症数据库,纳入2004至2012年接受SBRT(≤10次)的原发性≥5cm非小细胞肺癌患者201例。
主要发现
- 中位随访41.1个月,中位肿瘤大小5.5cm(四分位距5.0-6.0),cT2a、cT2b、cT3分别占24.9%、53.2%、21.9%。
- 中位SBRT总剂量和分次为50Gy/4次,92.5%患者接受≤5次分割。
- 中位总生存期为25.1个月;15%患者接受化疗,化疗组中位总生存期30.6个月 vs 23.4个月(P=.027)。
- 多变量分析中,年龄增加(HR 1.03,P=.012)、低分化肿瘤(HR 2.06,P=.049)、T3分期(HR 2.13,P=.005)与更差总生存相关。
- 多变量分析中化疗仍独立关联改善总生存(HR 0.57,P=.039)。
临床怎么用
- 对于≥5cm的非小细胞肺癌,SBRT可作为治疗选择,化疗可能改善总生存。
- 需前瞻性研究确定SBRT后化疗是否带来结局获益。
局限性
- 样本量低(201例),数据为假设生成性质,需前瞻性分析验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic body radiation therapy (SBRT) for ≥5 cm lesions is poorly defined, largely owing to the low sample sizes in existing studies. The present analysis examined the SBRT outcomes and assessed the effect of chemotherapy in this population. METHODS AND MATERIALS: The National Cancer Data Base was queried for primary non-small cell lung cancer ≥5 cm treated with SBRT (≤10 fractions). Patient, tumor, and treatment parameters were extracted. The primary outcome was overall survival (OS). Statistical methods involved Kaplan-Meier analysis and multivariable Cox proportional hazards modeling. RESULTS: From 2004 to 2012, data from 201 patients were analyzed. The median follow-up was 41.1 months. The median tumor size was 5.5 cm (interquartile range 5.0-6.0), with cT2a, cT2b, and cT3 disease in 24.9%, 53.2%, and 21.9%, respectively. The median total SBRT dose and fractionation was 50 Gy in 4 fractions, and 92.5% of the patients underwent SBRT with ≤5 fractions. The median OS was 25.1 months. Of the 201 patients, 15% received chemotherapy. The receipt of chemotherapy was associated with longer OS (median 30.6 vs 23.4 months; P=.027). On multivariable analysis, worse OS was seen with increasing age (hazard ratio [HR] 1.03; P=.012), poorly differentiated tumors (HR 2.06; P=.049), and T3 classification (HR 2.13; P=.005). On multivariable analysis, chemotherapy remained independently associated with improved OS (HR 0.57; P=.039). CONCLUSIONS: SBRT has utility in the setting of tumors ≥5 cm, with chemotherapy associated with improved OS in this subset. These hypothesis-generating data now raise the necessity of performing prospective analyses to determine whether chemotherapy confers outcome benefits after SBRT.
引用
- Verma V, McMillan MT, Grover S, et al. Stereotactic Body Radiation Therapy and the Influence of Chemotherapy on Overall Survival for Large (≥5 Centimeter) Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2016. PMID: 27843029. doi:10.1016/j.ijrobp.2016.09.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。